BMJ  1988;297:1092-1095 (29 October), doi:10.1136/bmj.297.6656.1092

Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria.

Service de Diabétologie, Hôpital Saint-Louis, Paris, France.

STUDY OBJECTIVE--To assess the effectiveness of inhibition of angiotensin converting enzyme in preventing diabetic nephropathy. DESIGN--Randomised follow up study of normotensive diabetics with persistent microalbuminuria (30-300 mg/24 hours) treated with enalapril or its matched placebo for one year. Double blind for first six months, single blind for last six months. SETTING--Diabetic clinic in tertiary referral centre. PATIENTS--Treatment group and placebo group each comprised 10 normotensive diabetics with persistent microalbuminuria. INTERVENTIONS--Treatment group was given enalapril 20 mg daily and controls matched placebo. Patients were given antihypertensive treatment after one year. END POINT--Albumin excretion, arterial pressure, and renal function. MAIN RESULTS--In last three months of trial three of 10 patients taking placebo had diabetic nephropathy (albumin excretion greater than 300 mg/24 hours). No patients taking enalapril developed nephropathy and five showed normal albumin excretion (less than 30 mg/24 hours) (p = 0.005, Mann-Whitney test). Mean arterial pressure was reduced by enalapril throughout study (p less than 0.005) but increased linearly with placebo (p less than 0.05). Albumin excretion decreased linearly with enalapril but not placebo. An increase in albumin excretion with placebo was positively related to the increase in mean arterial pressure (r = 0.709, p less than 0.05, Spearman's rank test). With enalapril total renal resistances and fractional albumin clearances improved progressively (time effect, p = 0.0001). CONCLUSION--Inhibition of angiotensin converting enzyme prevents development of nephropathy in normotensive diabetics with persistent microalbuminuria. This may be due to reduction in intraglomerular pressure and to prevention of increased systemic blood pressure. Future studies should compare long term effects of inhibitors of converting enzyme with other antihypertensive drugs.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

This article has been cited by other articles:

• Arfa, I., Abid, A., Nouira, S., Elloumi-Zghal, H., Malouche, D., Mannai, I., Zorgati, M. M., Ben Alaya, N., Rebai, A., Zouari, B., Ben Ammar, S., Ben Rayana, M. C., Hmida, S., Blousa-Chabchoub, S., Abdelhak, S. (2008). Lack of association between the angiotensin-converting enzyme gene (I/D) polymorphism and diabetic nephropathy in Tunisian type 2 diabetic patients. Journal of Renin-Angiotensin-Aldosterone System 9: 32-36 [Abstract]  
• Fischer, M. A., Choudhry, N. K., Winkelmayer, W. C. (2007). Impact Of Medicaid Prior Authorization On Angiotensin-Receptor Blockers: Can Policy Promote Rational Prescribing?. Health Aff (Millwood) 26: 800-807 [Abstract] [Full text]  
• Shankar, A., Klein, R., Klein, B. E.K., Nieto, F. J., Moss, S. E. (2007). Relationship Between Low-Normal Blood Pressure and Kidney Disease in Type 1 Diabetes. Hypertension 49: 48-54 [Abstract] [Full text]  
• Azizi, M., Menard, J. (2004). Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists. Circulation 109: 2492-2499 [Full text]  
• Fischer, M. A., Avorn, J. (2004). Economic Implications of Evidence-Based Prescribing for Hypertension: Can Better Care Cost Less?. JAMA 291: 1850-1856 [Abstract] [Full text]  
• Hollenberg, N. K. (2004). Treatment of the Patient With Diabetes Mellitus and Risk of Nephropathy: What Do We Know, and What Do We Need to Learn?. Arch Intern Med 164: 125-130 [Full text]  
• Simpson, S. H., Corabian, P., Jacobs, P., Johnson, J. A. (2003). The cost of major comorbidity in people with diabetes mellitus. CMAJ 168: 1661-1667 [Abstract] [Full text]  
• Poulsen, L. (2003). Review: Early renal involvement in Type 1 diabetes mellitus -- Part 2: ACE inhibitor intervention in Type 1 diabetes with low grade microalbuminuria. Journal of Renin-Angiotensin-Aldosterone System 4: 17-26 [Abstract]  
• Poulsen, L. (2002). Blood pressure and cardiac autonomic function in relation to risk factors and treatment perspectives in Type 1 diabetes. Journal of Renin-Angiotensin-Aldosterone System 3: 222-242 [Abstract]  
• The ACE Inhibitors in Diabetic Nephropathy Trialis, (2001). Should All Patients with Type 1 Diabetes Mellitus and Microalbuminuria Receive Angiotensin-Converting Enzyme Inhibitors? A Meta-Analysis of Individual Patient Data. ANN INTERN MED 134: 370-379 [Abstract] [Full text]  
• Bojestig, M., Nystrom, F. H, Arnqvist, H. J, Ludvigsson, J., Karlberg, B. E (2000). The renin-angiotensin-aldosterone system is suppressed in adults with Type 1 diabetes. Journal of Renin-Angiotensin-Aldosterone System 1: 353-356 [Abstract]  
• Hinson, J., Riordan, K., Hemphill, D., Randolph, C., Fonseca, V. (1997). Hypertension Education: An Important and Neglected Part of the Diabetes Education Curriculum?. The Diabetes Educator 23: 166-170  
• Ravid, M., Lang, R., Rachmani, R., Lishner, M. (1996). Long-term Renoprotective Effect of Angiotensin-converting Enzyme Inhibition in Non--insulin-dependent Diabetes Mellitus: A 7-Year Follow-up Study. Arch Intern Med 156: 286-289 [Abstract]  
• Maki, D. D., Ma, J. Z., Louis, T. A., Kasiske, B. L. (1995). Long-term Effects of Antihypertensive Agents on Proteinuria and Renal Function. Arch Intern Med 155: 1073-1080 [Abstract]  
• Manolio, T. A., Cutler, J. A., Furberg, C. D., Psaty, B. M., Whelton, P. K., Applegate, W. B. (1995). Trends in Pharmacologic Management of Hypertension in the United States. Arch Intern Med 155: 829-837 [Abstract]  
• Carella, M. J., Gossain, V. V., Rovner, D. R. (1994). Early Diabetic Nephropathy: Emerging Treatment Options. Arch Intern Med 154: 625-630 [Abstract]  
• Viberti, G., Mogensen, C. E., Groop, L. C., Pauls, J. F., the European Microalbuminuria Captopril Study Grou, , Boner, G., van Dyk, D. J., Lucas, A., Romero, R., Salinas, I., Sanmarti, A., Blomqvist, A. C., Ekstrand, A., Kirsi, V. L., Koivisto, V. A., Groop, L. C., Groop, P. H., Escobar, F., Jimenez, F. E., Campos-Pastor, M. M., Munoz, M., Gomez, M., Mangili, R., Pozza, G., Spotti, D., Hansen, K. W., Christiansen, J. S., Klein, F., Mogensen, C. E., van Doorn, L. G., Spooren, P. F. M. J., Cruickshank, J. K., Jervell, J., Paus, P. N., Collins, A., Viberti, G., Williams, G., Nelstrop, G. A. (1994). Effect of Captopril on Progression to Clinical Proteinuria in Patients With Insulin-Dependent Diabetes Mellitus and Microalbuminuria. JAMA 271: 275-279 [Abstract]  
• Nelson, R. G., Knowler, W. C., Pettitt, D. J., Saad, M. F., Charles, M. A., Bennett, P. H. (1991). Assessment of Risk of Overt Nephropathy in Diabetic Patients From Albumin Excretion in Untimed Urine Specimens. Arch Intern Med 151: 1761-1765 [Abstract]  
• Christlieb, A. R. (1990). Treatment Selection Considerations for the Hypertensive Diabetic Patient: A. Richard Christlieb, MD. Arch Intern Med 150: 1167-1174 [Abstract]  
• Noth, R. H., Krolewski, A. S., Kaysen, G. A., Meyer, T. W., Schambelan, M. (1989). Diabetic Nephropathy: Hemodynamic Basis and Implications for Disease Management. ANN INTERN MED 110: 795-813 [Abstract]  

Online poll

Find out more on doc2doc >>